ARTÍCULO ESPECIAL
Contribución de la Agencia Española de Medicamentos y Productos Sanitarios al Comité Europeo de Evaluación de Medicamentos de Uso Humano
Contribution of the Spanish Agency for Medicines and Healthcare Products to the European Committee for the Evaluation of Medicinal Products for Human Use
A. Alonso-Gutiérreza,
, P. Díaz-Ramosa, E. Sulleiro-Avendañoa, M. de Miguel-Marañóna, M.E. Padilla-Gallegoa, A. Sancho-Lópezb,c, S. Ruiz-Antúneza,c, C. Prieto-Yerroa,c
a Departamento de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, España
b Instituto de Investigación Sanitaria Puerta de Hierro, Madrid, España
c Miembro del Comité de Medicamentos de Uso Humano, Agencia Europea del Medicamento, Londres, Reino Unido
Leído
1044
Vecesse ha leído el artículo
650
Total PDF
394
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 0 | 1 | 1 |
| 2025 5 | 0 | 9 | 9 |
| 2025 4 | 0 | 1 | 1 |
| 2025 3 | 0 | 9 | 9 |
| 2025 2 | 0 | 3 | 3 |
| 2025 1 | 0 | 7 | 7 |
| 2024 12 | 0 | 3 | 3 |
| 2024 11 | 0 | 9 | 9 |
| 2024 10 | 0 | 7 | 7 |
| 2024 9 | 0 | 4 | 4 |
| 2024 8 | 0 | 5 | 5 |
| 2024 7 | 0 | 1 | 1 |
| 2024 6 | 0 | 6 | 6 |
| 2024 5 | 0 | 4 | 4 |
| 2024 4 | 0 | 4 | 4 |
| 2024 3 | 0 | 7 | 7 |
| 2024 2 | 0 | 2 | 2 |
| 2024 1 | 0 | 4 | 4 |
| 2023 12 | 0 | 9 | 9 |
| 2023 11 | 0 | 9 | 9 |
| 2023 10 | 0 | 12 | 12 |
| 2023 9 | 0 | 2 | 2 |
| 2023 8 | 0 | 5 | 5 |
| 2023 7 | 0 | 4 | 4 |
| 2023 6 | 0 | 5 | 5 |
| 2023 5 | 0 | 4 | 4 |
| 2023 4 | 0 | 2 | 2 |
| 2023 3 | 11 | 5 | 16 |
| 2023 2 | 0 | 9 | 9 |
| 2022 1 | 0 | 3 | 3 |
| 2022 12 | 0 | 4 | 4 |
| 2022 11 | 0 | 2 | 2 |
| 2022 10 | 0 | 4 | 4 |
| 2022 9 | 0 | 5 | 5 |
| 2022 8 | 0 | 3 | 3 |
| 2022 7 | 0 | 2 | 2 |
| 2022 6 | 0 | 6 | 6 |
| 2022 5 | 0 | 6 | 6 |
| 2022 4 | 0 | 6 | 6 |
| 2022 3 | 0 | 16 | 16 |
| 2022 2 | 0 | 8 | 8 |
| 2021 1 | 0 | 8 | 8 |
| 2021 12 | 0 | 7 | 7 |
| 2021 11 | 0 | 6 | 6 |
| 2021 10 | 0 | 11 | 11 |
| 2021 9 | 0 | 6 | 6 |
| 2021 8 | 0 | 10 | 10 |
| 2021 7 | 0 | 5 | 5 |
| 2021 6 | 0 | 6 | 6 |
| 2021 5 | 0 | 16 | 16 |
| 2021 4 | 0 | 12 | 12 |
| 2021 3 | 0 | 22 | 22 |
| 2021 2 | 0 | 13 | 13 |
| 2020 1 | 0 | 18 | 18 |
| 2020 12 | 0 | 16 | 16 |
| 2020 11 | 0 | 9 | 9 |
| 2020 10 | 0 | 5 | 5 |
| 2020 9 | 0 | 1 | 1 |
| 2020 8 | 0 | 6 | 6 |
| 2020 7 | 0 | 2 | 2 |
| 2020 6 | 0 | 4 | 4 |
| 2020 5 | 0 | 11 | 11 |
| 2020 4 | 0 | 8 | 8 |
| 2020 3 | 0 | 8 | 8 |
| 2020 2 | 0 | 9 | 9 |
| 2019 12 | 0 | 5 | 5 |
| 2019 11 | 0 | 4 | 4 |
| 2019 10 | 0 | 10 | 10 |
| 2019 9 | 0 | 4 | 4 |
| 2019 8 | 0 | 10 | 10 |
| 2019 7 | 0 | 10 | 10 |
| 2019 6 | 0 | 8 | 8 |
| 2019 5 | 0 | 8 | 8 |
| 2019 4 | 0 | 5 | 5 |
| 2019 3 | 0 | 2 | 2 |
| 2019 2 | 0 | 2 | 2 |
| 2019 1 | 0 | 1 | 1 |
| 2018 12 | 0 | 4 | 4 |
| 2018 11 | 0 | 2 | 2 |
| 2018 10 | 0 | 7 | 7 |
| 2018 9 | 0 | 1 | 1 |
| 2018 7 | 0 | 4 | 4 |
| 2018 6 | 0 | 2 | 2 |
| 2018 5 | 0 | 5 | 5 |
| 2018 4 | 0 | 1 | 1 |
| 2018 3 | 1 | 0 | 1 |
| 2018 2 | 117 | 1 | 118 |
| 2018 1 | 24 | 6 | 30 |
| 2017 12 | 102 | 2 | 104 |
| 2017 11 | 23 | 7 | 30 |
| 2017 10 | 26 | 6 | 32 |
| 2017 9 | 15 | 9 | 24 |
| 2017 8 | 15 | 6 | 21 |
| 2017 7 | 20 | 6 | 26 |
| 2017 6 | 19 | 10 | 29 |
| 2017 5 | 21 | 14 | 35 |
| 2017 4 | 0 | 1 | 1 |
| 2017 3 | 0 | 18 | 18 |
| 2017 2 | 0 | 8 | 8 |
| 2016 1 | 0 | 2 | 2 |
| 2016 12 | 0 | 1 | 1 |
| 2016 11 | 0 | 2 | 2 |
| 2016 10 | 0 | 4 | 4 |
| 2016 9 | 0 | 6 | 6 |
| 2016 7 | 0 | 1 | 1 |
| 2016 5 | 0 | 2 | 2 |
| 2016 4 | 0 | 3 | 3 |
| 2016 3 | 0 | 1 | 1 |
| 2015 1 | 0 | 3 | 3 |
Mostrar todo
